Heartland
The endocannabinoid system as a target for addiction treatment: Trials and tribulations
Addiction remains a major public health concern, and while pharmacotherapies can be effective, clinicians are limited by the paucity of existing interventions. Endocannabinoid signaling is involved in reward and addiction, which raises the possibility that drugs targeting this system could be used to treat substance use disorders. This review discusses findings from randomized controlled trials evaluating cannabinergic medications for addiction. Current evidence suggests that pharmacotherapies…

Review
. 2017 Sep 15;124:73-83.
doi: 10.1016/j.neuropharm.2017.05.031. Epub 2017 May 28.
Affiliations
Item in Clipboard
Review
Neuropharmacology. .
Abstract
Addiction remains a major public health concern, and while pharmacotherapies can be effective, clinicians are limited by the paucity of existing interventions. Endocannabinoid signaling is involved in reward and addiction, which raises the possibility that drugs targeting this system could be used to treat substance use disorders. This review discusses findings from randomized controlled trials evaluating cannabinergic medications for addiction. Current evidence suggests that pharmacotherapies containing delta-9-tetrahydrocannabinol, such as dronabinol and nabiximols, are effective for cannabis withdrawal. Dronabinol may also reduce symptoms of opioid withdrawal. The cannabinoid receptor 1 (CB1) inverse agonist rimonabant showed promising effects for smoking cessation but also caused psychiatric side effects and currently lacks regulatory approval. Few trials have investigated cannabinergic medications for alcohol use disorder. Overall, the endocannabinoid system remains a promising target for addiction treatment. Development of novel medications such as fatty acid amide hydrolase inhibitors and neutral CB1 antagonists promises to extend the range of available interventions. This article is part of the Special Issue entitled “A New Dawn in Cannabinoid Neurobiology”.
Keywords: Cannabidiol; Cannabinoid antagonists; Clinical trial; Dronabinol; Endocannabinoids; Smoking cessation; Substance use disorders; Withdrawal.
Copyright © 2017. Published by Elsevier Ltd.
Similar articles
-
Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice.
AAPS J. 2009 Jun;11(2):342-52. doi: 10.1208/s12248-009-9110-7. Epub 2009 May 9. AAPS J. 2009. PMID: 19430909 Free PMC article.
-
Role of the endocannabinoid system in drug addiction.
Biochem Pharmacol. 2018 Nov;157:108-121. doi: 10.1016/j.bcp.2018.09.013. Epub 2018 Sep 12. Biochem Pharmacol. 2018. PMID: 30217570 Review.
-
Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
Physiol Behav. 2008 Mar 18;93(4-5):671-86. doi: 10.1016/j.physbeh.2007.11.012. Epub 2007 Nov 21. Physiol Behav. 2008. PMID: 18155257 Free PMC article. Review.
-
Endocannabinoids and striatal function: implications for addiction-related behaviours.
Behav Pharmacol. 2015 Feb;26(1-2):59-72. doi: 10.1097/FBP.0000000000000109. Behav Pharmacol. 2015. PMID: 25369747 Free PMC article. Review.
-
Involvement of the endocannabinoid system in drug addiction.
Trends Neurosci. 2006 Apr;29(4):225-32. doi: 10.1016/j.tins.2006.01.008. Epub 2006 Feb 17. Trends Neurosci. 2006. PMID: 16483675 Review.
Cited by 16 articles
-
Therapeutic potential of opioid/cannabinoid combinations in humans: Review of the evidence.
Eur Neuropsychopharmacol. 2020 Jul;36:206-216. doi: 10.1016/j.euroneuro.2020.03.002. Epub 2020 Apr 6. Eur Neuropsychopharmacol. 2020. PMID: 32273144
-
GPCR and Alcohol-Related Behaviors in Genetically Modified Mice.
Neurotherapeutics. 2020 Jan;17(1):17-42. doi: 10.1007/s13311-019-00828-y. Neurotherapeutics. 2020. PMID: 31919661 Review.
-
Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB.
Neuropsychopharmacology. 2020 Jul;45(8):1289-1296. doi: 10.1038/s41386-020-0606-2. Epub 2020 Jan 7. Neuropsychopharmacology. 2020. PMID: 31910433
-
Characteristics of Dispensary Patients that Limit Alcohol after Initiating Cannabis.
J Psychoactive Drugs. 2020 Apr-Jun;52(2):145-152. doi: 10.1080/02791072.2019.1694199. Epub 2019 Dec 7. J Psychoactive Drugs. 2020. PMID: 31813342
-
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
CNS Drugs. 2019 Oct;33(10):1001-1030. doi: 10.1007/s40263-019-00664-w. CNS Drugs. 2019. PMID: 31549358
Publication types
MeSH terms
Substances
LinkOut – more resources
-
Full Text Sources
-
Medical
-
Heartland1 week ago
CBD Oil for Dogs With Seizures: The Ultimate Guide
-
Heartland1 day ago
CBD Vape Oil Market 2021: Global Trends, Business Overview, Challenges, Opportunities …
-
Heartland7 days ago
Florida Bill Aims to Legalize Medical Magic Mushrooms
-
Heartland7 days ago
Delta 8: Shipping Vape Ban Goes Into Effect Soon – What Does It Means?
-
Heartland6 days ago
Explained: How CBD Oil is Different Than CBD Capsule?
-
Heartland1 week ago
Affordable cbd oil?
-
Heartland1 week ago
…
-
Material1 week ago
Dielectric properties and potential applications of alizarin yellow GG-Cu(II) complex film blended with polyvinyl alcohol